Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell ...

Bayer announces finerenone meets primary endpoint in pivotal phase III FIND-CKD study in patients with non-diabetic chronic kidney disease: Berlin Tuesday, March 17, 2026, 15:00 H ...

The Phase III study FIND-CKD ( NCT05047263) — investigating the efficacy and safety of KERENDIA ® (finerenone) versus placebo when added to standard of care in adult patients with non-diabetic chronic ...

Clinical update on track for Q2 2026 for Phase 2 trial of silevertinib in patients with non-classical EGFRm NSCLC, including preliminary DOR and ...

Clinical update on track for Q2 2026 for Phase 2 trial of silevertinib in patients with non-classical EGFRm NSCLC, including preliminary DOR and PFS data in frontline settingCompany is preparing to in ...

Type 2 diabetes mellitus (T2DM) represents a mounting global health crisis. India, home to 17.78% of the world's population, ...

Therapeutic progress in lung squamous cell carcinoma has lagged, with recent antiangiogenic–checkpoint inhibitor combinations failing primary endpoints despite improved safety, underscoring unmet need ...

Eledon Pharmaceuticals, Inc. is rated a Strong Buy following positive phase 2 BESTOW results for tegoprubart. Read more on ELDN stock here.

A new study links AKI recovery thresholds to long-term kidney failure and mortality risk. Discover why a 10% creatinine recovery matters.

The FDA accepted a Biologics License Application for imlifidase for the desensitization treatment of highly sensitized adult kidney transplant patients.

A new analysis of hypertension guidelines suggests some older adults — mostly women — with slightly high blood pressure could safely hold off on medications if they’re in good health.